In silico optimization of pharmacokinetic properties and receptor binding affinity simultaneously: a ‘parallel progression approach to drug design’ applied to β-blockers

References

• Baek, I., Yun, M., Yun, H., & Kwon, K. (2008). Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans. Archives of Pharmacal Research, 31, 814–821.10.1007/s12272-001-1231-4
   PubMed Web of Science ®Google Scholar
• Coleman, M. D. (2010). Human drug metabolism: An introduction. Chichester, UK: Wiley.10.1002/9780470689332
   Google Scholar
• del Amo, E. M., Ghemtio, L., Xhaard, H., Yliperttula, M., Urtti, A., & Kidron, H. (2013). Applying linear and non-linear methods for parallel prediction of volume of distribution and fraction of unbound drug. PLoS One, 8, e74758.10.1371/journal.pone.0074758
   PubMed Web of Science ®Google Scholar
• de Mey, C., Breithaupt, K., Schloos, J., Neugebauer, G., Palm, D., & Belz, G. G. (1994). Dose-effect and pharmacokinetic-pharmacodynamic relationships of the β1adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. Clinical Pharmacology & Therapeutics, 55, 329–337.
   PubMed Web of Science ®Google Scholar
• Desmond. (2012). Molecular dynamics system, maestro-desmond interoperability tools version 3.1. New York, NY: Schrödinger.
   Google Scholar
• Doddareddy, M. R., Lee, Y. J., Cho, Y. S., Choi, K. I., Koh, H. Y., & Pae, A. N. (2004). Hologram quantitative structure activity relationship studies on 5-HT 6 antagonists. Bioorganic & Medicinal Chemistry, 12, 3815–3824.
   PubMed Web of Science ®Google Scholar
• Fernandez-Fuentes, N., Madrid-Aliste, C. J., Rai, B. K., Fajardo, J. E., & Fiser, A. (2007). M4T: A comparative protein structure modeling server. Nucleic Acids Research, 35, W363–W368.10.1093/nar/gkm341
   PubMed Web of Science ®Google Scholar
• Fielden, M. R., & Kolaja, K. L. (2008). The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opinion on Drug Safety, 7, 107–110.
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., … Perry, J. K. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47, 1739–1749.10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Frishman, W. H., & Saunders, E. (2011). β-Adrenergic blockers. The Journal of Clinical Hypertension, 13, 649–653.10.1111/jch.2011.13.issue-9
   PubMed Web of Science ®Google Scholar
• Gobburu, J. V., & Shelver, W. H. (1995). Quantitative structure–pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks. Journal of Pharmaceutical Sciences, 84, 862–865.10.1002/(ISSN)1520-6017
   PubMed Web of Science ®Google Scholar
• Gombar, V. K., & Hall, S. D. (2013). Quantitative structure-activity relationship models of clinical pharmacokinetics: Clearance and volume of distribution. Journal of Chemical Information and Modeling, 53, 948–957.10.1021/ci400001u
   PubMed Web of Science ®Google Scholar
• GPCRDB. (http://www.gpcr.org/7tm/).
   Google Scholar
• Heritage, T. W., & Lowis, D. R. (1999). Molecular hologram QSAR. In A. L. Parrill & M. R. Reddy (Eds.), Rational drug design: Novel methodology and practical applications (ch. 14, pp. 212–225). ACS Symposium Series 719. Washington, DC: American Chemical Society.
   Google Scholar
• Hinderling, P. H., Schmidlin, O., & Seydel, J. K. (1984). Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man. Journal of Pharmacokinetics and Biopharmaceutics, 12, 263–287.10.1007/BF01061721
   PubMedGoogle Scholar
• Hlavica, P. (2006). Functional interaction of nitrogenous organic bases with cytochrome P450: A critical assessment and update of substrate features and predicted key active-site elements steering the access, binding, and orientation of amines. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 1764, 645–670.10.1016/j.bbapap.2006.01.013
   PubMed Web of Science ®Google Scholar
• Höcht, C., DiVerniero, C., Opezzo, J. A., & Taira, C. A. (2005). Applicability of microdialysis as a technique for pharmacokinetic–pharmacodynamic (PK–PD) modeling of antihypertensive beta-blockers. Journal of Pharmacological and Toxicological Methods, 52, 244–250.10.1016/j.vascn.2005.01.002
   PubMedGoogle Scholar
• Holford, N. (1990). Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling. Fundamental & Clinical Pharmacology, 4, 93s–101s.
   PubMed Web of Science ®Google Scholar
• Hooft, R. W., Sander, C., & Vriend, G. (1997). Objectively judging the quality of a protein structure from a Ramachandran plot. Computer Applications in the Biosciences, CABIOS, 13, 425–430.
   PubMedGoogle Scholar
• Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14, 33–38.10.1016/0263-7855(96)00018-5
   PubMed Web of Science ®Google Scholar
• Karalis, V., Tsantili-Kakoulidou, A., & Macheras, P. (2002). Multivariate statistics of disposition pharmacokinetic parameters for structurally unrelated drugs used in therapeutics. Pharmaceutical Research, 19, 1827–1834.10.1023/A:1021489323828
   PubMed Web of Science ®Google Scholar
• Koopmans, R., Oosterhuis, B., Karemaker, J., Wemer, J., & Van Boxtel, C. (1988). Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring. European Journal of Clinical Pharmacology, 34, 395–400.10.1007/BF00542442
   PubMed Web of Science ®Google Scholar
• Koopmans, R., Oosterhuis, B., Karemaker, J., Wemer, J., & van Boxtel, C. (1993). The effect of oxprenolol dosage time on its pharmacokinetics and haemodynamic effects during exercise in man. European Journal of Clinical Pharmacology, 44, 171–176.10.1007/BF00315476
   PubMed Web of Science ®Google Scholar
• Kubinyi, H. (1997). QSAR and 3D QSAR in drug design part 2: Applications and problems. Drug Discovery Today, 2, 538–546.10.1016/S1359-6446(97)01084-2
   Web of Science ®Google Scholar
• Läer, S., Elshoff, J.-P., Meibohm, B., Weil, J., Mir, T. S., Zhang, W., & Hulpke-Wette, M. (2005). Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. Journal of the American College of Cardiology, 46, 1322–1330.10.1016/j.jacc.2005.06.061
   PubMed Web of Science ®Google Scholar
• Laskowski, R. A., Chistyakov, V. V., & Thornton, J. M. (2005). PDBsum more: New summaries and analyses of the known 3D structures of proteins and nucleic acids. Nucleic Acids Research, 33, D266–D268.
   PubMed Web of Science ®Google Scholar
• Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993). PROCHECK: A program to check the stereochemical quality of protein structures. Journal of Applied Crystallography, 26, 283–291.10.1107/S0021889892009944
   Web of Science ®Google Scholar
• Lomize, M. A., Pogozheva, I. D., Joo, H., Mosberg, H. I., & Lomize, A. L. (2012). OPM database and PPM web server: Resources for positioning of proteins in membranes. Nucleic Acids Research, 40, D370–D376.10.1093/nar/gkr703
   PubMed Web of Science ®Google Scholar
• Lowis, D. R. (1997). HQSAR: A new, highly predictive QSAR technique. Tripos Technical Notes, 1, 1–15.
   Google Scholar
• Mager, D. E., & Jusko, W. J. (2002). Quantitative structure–pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. Journal of Pharmaceutical Sciences, 91, 2441–2451.10.1002/(ISSN)1520-6017
   PubMed Web of Science ®Google Scholar
• Mark, P., & Nilsson, L. (2001). Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. The Journal of Physical Chemistry A, 105, 9954–9960.10.1021/jp003020w
   Web of Science ®Google Scholar
• Mayer, J. M., & Van De Waterbeemd, H. (1985). Development of quantitative structure-pharmacokinetic relationships. Environmental Health Perspectives, 61, 295–306.
   PubMed Web of Science ®Google Scholar
• Melo, F., & Feytmans, E. (1998). Assessing protein structures with a non-local atomic interaction energy. Journal of Molecular Biology, 277, 1141–1152.10.1006/jmbi.1998.1665
   PubMed Web of Science ®Google Scholar
• Obach, R. S., Lombardo, F., & Waters, N. J. (2008). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metabolism and Disposition, 36, 1385–1405.10.1124/dmd.108.020479
   PubMed Web of Science ®Google Scholar
• Pratim Roy, P., Paul, S., Mitra, I., & Roy, K. (2009). On two novel parameters for validation of predictive QSAR models. Molecules, 14, 1660–1701.10.3390/molecules14051660
   PubMed Web of Science ®Google Scholar
• Raunio, H. (2011). In silico toxicology-non-testing methods. Frontiers in Pharmacology, 2, 1–8.
   PubMed Web of Science ®Google Scholar
• Rodríguez, D., Bello, X., & Gutiérrez-de-Terán, H. (2012). Molecular modelling of G protein-coupled receptors through the web. Molecular Informatics, 31, 334–341.10.1002/minf.v31.5
   PubMed Web of Science ®Google Scholar
• Roy, A., Kucukural, A., & Zhang, Y. (2010). I-TASSER: A unified platform for automated protein structure and function prediction. Nature Protocols, 5, 725–738.10.1038/nprot.2010.5
   PubMed Web of Science ®Google Scholar
• Shaw, D. E. (2005). A fast, scalable method for the parallel evaluation of distance-limited pairwise particle interactions. Journal of Computational Chemistry, 26, 1318–1328.10.1002/(ISSN)1096-987X
   PubMed Web of Science ®Google Scholar
• Shen, M. Y., & Sali, A. (2006). Statistical potential for assessment and prediction of protein structures. Protein Science, 15, 2507–2524.10.1110/(ISSN)1469-896X
   PubMed Web of Science ®Google Scholar
• Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W., … Söding, J. (2011). Fast, scalable generation of high‐quality protein multiple sequence alignments using Clustal Omega. Molecular Systems Biology, 7, 539, 1–6.
   PubMed Web of Science ®Google Scholar
• Steeg, T., Freijer, J., Danhof, M., & Lange, E. (2007). Pharmacokinetic-pharmacodynamic modelling of S (−)-atenolol in rats: Reduction of isoprenaline-induced tachycardia as a, continuous pharmacodynamic endpoint. British Journal of Pharmacology, 151, 356–366.
   PubMed Web of Science ®Google Scholar
• Studio, D. (2010). 3.0-advanced software package for life science researchers. San Diego, CA: Accelrys.
   Google Scholar
• Talevi, A., Goodarzi, M., Ortiz, E. V., Duchowicz, P. R., Bellera, C. L., Pesce, G., … Bruno-Blanch, L. E. (2011). Prediction of drug intestinal absorption by new linear and non-linear QSPR. European Journal of Medicinal Chemistry, 46, 218–228.10.1016/j.ejmech.2010.11.005
   PubMed Web of Science ®Google Scholar
• Testa, B., Crivori, P., Reist, M., & Carrupt, P.-A. (2000). The influence of lipophilicity on the pharmacokinetic behavior of drugs: Concepts and examples. Perspectives in Drug Discovery and Design, 19, 179–211.10.1023/A:1008741731244
   Google Scholar
• Theil, F.-P., Guentert, T. W., Haddad, S., & Poulin, P. (2003). Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicology Letters, 138, 29–49.10.1016/S0378-4274(02)00374-0
   PubMed Web of Science ®Google Scholar
• Turner, J. V., Maddalena, D. J., & Cutler, D. J. (2004). Pharmacokinetic parameter prediction from drug structure using artificial neural networks. International Journal of Pharmaceutics, 270, 209–219.10.1016/j.ijpharm.2003.10.011
   PubMed Web of Science ®Google Scholar
• Vaz, R. J., Nayeem, A., Santone, K., Chandrasena, G., & Gavai, A. V. (2005). A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series. Bioorganic & Medicinal Chemistry Letters, 15, 3816–3820.
   PubMed Web of Science ®Google Scholar
• Velikanov, M., Yan, L., Badretdinov, A., & Szalma, S. (2001). Resource center. Presented at the 4th International Conference on Molecular Structural Biology (ICMSB 2001), Vienna, Austria.
   Google Scholar
• Warne, T., Serrano-Vega, M. J., Baker, J. G., Moukhametzianov, R., Edwards, P. C., Henderson, R., … Schertler, G. F. (2008). Structure of a β1-adrenergic G-protein-coupled receptor. Nature, 454, 486–491.10.1038/nature07101
   PubMed Web of Science ®Google Scholar
• Wessel, M. D., Jurs, P. C., Tolan, J. W., & Muskal, S. M. (1998). Prediction of human intestinal absorption of drug compounds from molecular structure. Journal of Chemical Information and Computer Sciences, 38, 726–735.
   PubMedGoogle Scholar
• Worth, C. L., Kreuchwig, A., Kleinau, G., & Krause, G. (2011). GPCR-SSFE: A comprehensive database of G-protein-coupled receptor template predictions and homology models. BMC Bioinformatics, 12, 185.10.1186/1471-2105-12-185
   PubMed Web of Science ®Google Scholar
• Yamashita, F., & Hashida, M. (2004). In silico approaches for predicting ADME properties of drugs. Drug Metabolism and Pharmacokinetics, 19, 327–338.10.2133/dmpk.19.327
   PubMedGoogle Scholar
• Yap, C., Li, Z., & Chen, Y. (2006). Quantitative structure–pharmacokinetic relationships for drug clearance by using statistical learning methods. Journal of Molecular Graphics and Modelling, 24, 383–395.10.1016/j.jmgm.2005.10.004
   PubMed Web of Science ®Google Scholar
• Zhang, Y. (2008). I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 9, 40.10.1186/1471-2105-9-40
   PubMed Web of Science ®Google Scholar